
xCELLIGENCE SYSTEM

GPCR-MEDIATED SIGNALING

PUBLICATION LIST

RELEVANT DATA, REMARKABLE PUBLICATIONS

Accelerate your research and increase your productivity with pioneering real-time cellular analysis.
If you identify any missing publications, please send the citation to PUBLICATIONS@ACEABIO.COM.

1. Yu N1, Atienza JM, Bernard J, Blanc S, Zhu J, Wang X, Xu X, Abassi YA. **Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors.** [Anal Chem](#). 2006 Jan 1;78(1):35-43.
2. Xi B1, Yu N, Wang X, Xu X, Abassi YA. **The application of cell-based label-free technology in drug discovery.** [Biotechnol J](#). 2008 Apr;3(4):484-95.
3. Birker-Robaczewska M1, Studer R, Haenig B, Menyhart K, Hofmann S, Nayler O. **bFGF induces S1P1 receptor expression and functionality in human pulmonary artery smooth muscle cells.** [J Cell Biochem](#). 2008 Nov 1;105(4):1139-45.
4. Xie Z1, Vallender EJ, Yu N, Kirstein SL, Yang H, Bahn ME, Westmoreland SV, Miller GM. **Cloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic association.** [J Neurosci Res](#). 2008 Nov 15;86(15):3435-46.
5. Shemesh R1, Hermesh C, Toporik A, Levine Z, Novik A, Wool A, Kliger Y, Rosenberg A, Bathgate RA, Cohen Y. **Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursor.** [Ann N Y Acad Sci](#). 2009 Apr;1160:78-86.
6. Yanagida K1, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, Shimizu T, Ishii S. **Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6.** [J Biol Chem](#). 2009 Jun 26;284(26):17731-41.
7. Scott CW1, Peters MF. **Label-free whole-cell assays: expanding the scope of GPCR screening.** [Drug Discov Today](#). 2010 Sep;15(17-18):704-16.
8. Scandroglio P1, Brusa R, Lozza G, Mancini I, Petrò R, Reggiani A, Beltramo M. **Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology.** [J Biomol Screen](#). 2010 Dec;15(10):1238-47.

9. Kammermann M1, Denelavas A, Imbach A, Grether U, Dehmlow H, Apfel CM, Hertel C. **Impedance measurement: a new method to detect ligand-biased receptor signaling.** [Biochem Biophys Res Commun.](#) 2011 Sep 2;412(3):419-24.
10. Irelan JT1, Wu MJ, Morgan J, Ke N, Xi B, Wang X, Xu X, Abassi YA. **Rapid and quantitative assessment of cell quality, identity, and functionality for cell-based assays using real-time cellular analysis.** [J Biomol Screen.](#) 2011 Mar;16(3):313-22.
11. Boitano S1, Flynn AN, Schulz SM, Hoffman J, Price TJ, Vagner J. **Potent agonists of the protease activated receptor 2 (PAR2).** [J Med Chem.](#) 2011 Mar 10;54(5):1308-13.
12. White GE1, McNeill E, Christou I, Channon KM, Greaves DR. **Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade.** [Mol Pharmacol.](#) 2011 Aug;80(2):328-36.
13. Flynn AN1, Tillu DV, Asiedu MN, Hoffman J, Vagner J, Price TJ, Boitano S. **The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.** [J Biol Chem.](#) 2011 May 27;286(21):19076-88.
14. Watts AO1, Scholten DJ, Heitman LH, Vischer HF, Leurs R. **Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.** [Biochem Biophys Res Commun.](#) 2012 Mar 9;419(2):412-8.
15. Halai R1, Croker DE2, Suen JY3, Fairlie DP4, Cooper MA5. **A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling.** [Biosensors \(Basel\).](#) 2012 Jul 26;2(3):273-90.
16. Guo D1, Mulder-Krieger T, IJzerman AP, Heitman LH. **Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.** [Br J Pharmacol.](#) 2012 Jul;166(6):1846-59.
17. Wilson JL1, Taylor L, Polgar P. **Endothelin-1 activation of ETB receptors leads to a reduced cellular proliferative rate and an increased cellular footprint.** [Exp Cell Res.](#) 2012 Jun 10;318(10):1125-33.
18. Stallaert W1, Dorn JF, van der Westhuizen E, Audet M, Bouvier M. **Impedance responses reveal β_2 -adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles.** [PLoS One.](#) 2012;7(1):e29420.
19. Gan AM1, Butoi ED, Manea A, Simion V, Stan D, Parvulescu MM, Calin M, Manduteanu I, Simionescu M. **Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways.** [Cell Tissue Res.](#) 2013 Jan;351(1):161-74.
20. Yuan L1, Zhang H, Liu J, Rubin JB, Cho YJ, Shu HK, Schniederjan M, MacDonald TJ. **Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration.** [Mol Cancer.](#) 2013 Mar 5;12:18.

21. Zweemer AJ1, Nederpelt I, Vrieling H, Hafith S, Doornbos ML, de Vries H, Abt J, Gross R, Stamos D, Saunders J, Smit MJ, Ijzerman AP, Heitman LH. **Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2.** [Mol Pharmacol](#). 2013 Oct;84(4):551-61.
22. Urban C1, Hamacher A, Partke HJ, Roden M, Schinner S, Christiansen E, Due-Hansen ME, Ulven T, Gohlke H, Kassack MU. **In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469.** [Naunyn Schmiedebergs Arch Pharmacol](#). 2013 Dec;386(12):1021-30.
23. Fischer RM1, Fontinha BM, Kirchmaier S, Steger J, Bloch S, Inoue D, Panda S, Rumpel S, Tessmar-Raible K. **Co-expression of VAL- and TMT-opsins uncovers ancient photosensory interneurons and motorneurons in the vertebrate brain.** [PLoS Biol](#). 2013;11(6):e1001585.
24. Marinova Z1, Walitza S, Grünblatt E. **5-HT_{2A} serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: role of the ERK pathway.** [Prog Neuropsychopharmacol Biol Psychiatry](#). 2013 Jul 1;44:64-72.
25. Flynn AN1, Hoffman J, Tillu DV, Sherwood CL, Zhang Z, Patek R, Asiedu MN, Vagner J, Price TJ, Boitano S. **Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.** [FASEB J](#). 2013 Apr;27(4):1498-510. doi: 10.1096/fj.12-217323. Epub 2013 Jan 4.
26. Halai R1, Bellows-Peterson ML2, Branchett W3, Smadbeck J2, Kieslich CA4, Croker DE1, Cooper MA1, Morikis D5, Woodruff TM6, Floudas CA7, Monk PN8. **Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.** [Eur J Pharmacol](#). 2014 Dec 15;745:176-81.
27. Chen AN1, Malone DT1, Pabreja K1, Sexton PM1, Christopoulos A1, Canals M2. **Detection and quantification of allosteric modulation of endogenous m4 muscarinic acetylcholine receptor using impedance-based label-free technology in a neuronal cell line.** [J Biomol Screen](#). 2015 Jun;20(5):646-54.
28. Ke N1, Nguyen K, Irelan J, Abassi YA. **Multidimensional GPCR profiling and screening using impedance-based label-free and real-time assay.** [Methods Mol Biol](#). 2015;1272:215-26.